deflazacort (Emflaza)
Jump to navigation
Jump to search
Indications
- treatment of Duchenne muscular dystrophy in children >= 5 years of age[1]
Dosage
- 0.9 mg/kg/day PO once daily.
- tablet, oral suspension
Adverse effects
- similar to other glucocorticoids
Mechanism of action
- glucorticoid that reduces inflammation
- oxazoline derivative of prednisolone
More general terms
References
- ↑ Jump up to: 1.0 1.1 FDA News Release. February 9, 2017 FDA approves drug to treat Duchenne muscular dystrophy. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm540945.htm
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Griggs RC, Miller JP, Greenberg CR et al Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016 Nov 15;87(20):2123-2131. Epub 2016 Aug 26. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27566742 Free PMC Article